Project UpdateJul 9, 2026, 08:02 AM
Century Therapeutics to Present CNTY-813 Data; Targets Q4 2026 IND
AI Summary
Century Therapeutics announced that abstracts for its CNTY-813 program have been accepted for oral presentations at two upcoming scientific congresses: the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and the Breakthrough T1D® Clinical & Research Congress 2026 (CRC 2026). CNTY-813 is an iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes. The company is targeting an Investigational New Drug (IND) submission for CNTY-813 in the fourth quarter of 2026.
Key Highlights
- Abstracts accepted for oral presentations at the 62nd EASD Annual Meeting and CRC 2026.
- Presentations will highlight CNTY-813, an iPSC-derived islet replacement therapy for Type 1 Diabetes.
- CNTY-813 is engineered with Allo-Evasion™ 5.0, Century's proprietary immune evasion technology.
- Preclinical data demonstrated robust glucose-responsive function and a favorable safety profile.
- Century Therapeutics is targeting an Investigational New Drug (IND) submission for CNTY-813 in Q4 2026.
Price Impact
More from IPSC